Atara Biotherapeutics Inc (NASDAQ:ATRA) shares were up 14.1% on Tuesday . The company traded as high as $45.20 and last traded at $45.05. Approximately 1,017,194 shares changed hands during mid-day trading, a decline of 19% from the average daily volume of 1,250,680 shares. The stock had previously closed at $39.47.

A number of research analysts have weighed in on ATRA shares. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. ValuEngine raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 6th. BidaskClub raised shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Finally, Cowen started coverage on shares of Atara Biotherapeutics in a research note on Friday, January 26th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $30.60.

The firm has a market capitalization of $1,210.00, a PE ratio of -12.98 and a beta of 2.71.

In other news, CEO Isaac E. Ciechanover sold 2,200 shares of the business’s stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $15.15, for a total value of $33,330.00. Following the sale, the chief executive officer now owns 743,675 shares of the company’s stock, valued at $11,266,676.25. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Heather D. Turner sold 12,214 shares of the business’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $38.01, for a total transaction of $464,254.14. Following the completion of the sale, the executive vice president now directly owns 77,112 shares in the company, valued at approximately $2,931,027.12. The disclosure for this sale can be found here. In the last three months, insiders sold 280,702 shares of company stock worth $7,176,829. 16.20% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. increased its holdings in Atara Biotherapeutics by 16.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 92,974 shares of the biotechnology company’s stock worth $1,302,000 after buying an additional 13,394 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Atara Biotherapeutics by 4.7% during the second quarter. Bank of New York Mellon Corp now owns 125,713 shares of the biotechnology company’s stock worth $1,760,000 after buying an additional 5,616 shares during the last quarter. Alliancebernstein L.P. increased its holdings in Atara Biotherapeutics by 49.6% during the second quarter. Alliancebernstein L.P. now owns 27,740 shares of the biotechnology company’s stock worth $388,000 after buying an additional 9,200 shares during the last quarter. Teachers Advisors LLC increased its holdings in Atara Biotherapeutics by 2.4% during the second quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock worth $660,000 after buying an additional 1,110 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its holdings in Atara Biotherapeutics by 7.4% during the second quarter. TIAA CREF Investment Management LLC now owns 67,892 shares of the biotechnology company’s stock worth $950,000 after buying an additional 4,661 shares during the last quarter. 69.58% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://theolympiareport.com/2018/02/13/atara-biotherapeutics-atra-trading-up-14-1.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.